MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

Completed · Phase 1/Phase 2

Conditions studied: Metastatic Colorectal Cancer

In brief

Open-label, dose-confirmation and cohort expansion, multicenter, Phase Ib/II study to assess the anti-tumor activity and safety of MEN1611 in combination with cetuximab for the treatment of participants with phosphatidylinositol 3-kinase, catalytic, alpha polypeptide gene (PIK3CA)-mutated metastatic colorectal cancer.

Key facts

Study ID
NCT04495621
Run by
Menarini Group
People needed
29
Starts
2020-07-20
Expected to finish
2024-02-27
Last updated by the study team
2025-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.